| EQT |
Report |
Adjusted EPS |
BEAT |
pred ~$0.46 vs. cons $0.41 |
MEDIUM |
| EQT |
Report |
Total revenue |
BEAT |
pred ~$1.85bn vs. cons $1.79bn |
MEDIUM |
| EQT |
Report |
Free cash flow attributable to EQT |
MISS |
pred ~$250m vs. cons $275m |
LOW |
| EQT |
Guide |
Full-year 2026 total sales volume |
UNCHANGED |
guide ~2,325 Bcfe vs. cons 2,325 Bcfe (FY2026) |
MEDIUM |
| EQT |
Guide |
Full-year 2026 total capital expenditures |
UNCHANGED |
guide ~$2.75bn vs. cons $2.75bn (FY2026) |
MEDIUM |
| EQT |
Guide |
Full-year 2026 operating costs |
UNCHANGED |
guide ~$1.14/Mcfe vs. cons $1.14/Mcfe (FY2026) |
MEDIUM |
| EQT |
Guide |
Year-end net debt target |
UNCHANGED |
guide ~$5.0bn vs. cons $5.1bn (FY2026) |
LOW |
| EQT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| EQT |
Return |
5-day cumulative residual |
-4.0% (FOLLOW-THROUGH) |
EPS and revenue beat estimates by ~$0.05/share and ~$0.06bn, respectively, but predicted FCF of ~$250m versus ~$275m consensus and an unchanged ~$2.75bn FY2026 capital plan leave out-period cash-flow math softer; revisions should drift lower after the initial reaction. |
MEDIUM |